Pembrolizumab,Axitinib,Sunitinib,Lenvatinib,Everolimus,Nivolumab,Ipilimumab,Cabozantinib
Merck,Pfizer,eisai,BMS
['biomarker', 'nivo', 'rcc,(-irccs),(-srcc),(-urcc)', 'ipi/']
imdc favorable risk rcc after #asco2023. similar to itt, early disease control for io/tki regimens and durability for ipi/nivo showing some favorable risk pts are immune-responsive. biomarkers to select and to de-intensify treatment are needed. 